Trial · NCT02495844
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 75 % Responder Rate During the 2-week Inpatient Period | During the 2-week Inpatient Period | The 75% responder rate is defined as the percentage of subjects with a 75 % or greater reduction in focal seizure frequency during the 2-week Inpatient Period compared with the Baseline Period. |
| Secondary | Median Percent Change in Weekly Focal Seizure Frequency During the 2-week Inpatient Period | During the 2-week Inpatient Period | A negative value in median percent change reflects a reduction from Baseline. |
| Secondary | Median Percent Change in Weekly Focal Seizure Frequency During the Outpatient Maintenance Period | During the Outpatient Maintenance Period (8 weeks) | A negative value in median percent change reflects a reduction from Baseline. |
| Secondary | Median Percent Change in Weekly Focal Seizure Frequency During the On-UCB0942 Overall Period | During the On-UCB0942 Overall Period (approximately 11 weeks) | A negative value in median percent change reflects a reduction from Baseline. |
| Secondary | Seizure-free Rate (All Seizures) During the 2-week Inpatient Period | During the 2-week Inpatient Period | Seizure-free rate is reported as the percentage of seizure-free participants during the 2-week Inpatient Period. |
| Secondary | Seizure-free Rate (All Seizures) During the Last 4 Weeks of the Outpatient Maintenance Period | During the last 4 weeks of the Outpatient Maintenance Period | Seizure-free rate is reported as the percentage of seizure-free participants during the last 4 weeks of the Outpatient Maintenance Period. |
| Secondary | Seizure-free Rate (All Seizures) During the On-UCB0942 Overall Period | During the On-UCB0942 Overall Period (approximately 11 weeks) | Seizure-free rate is reported as the percentage of seizure-free participants during the On-UCB0942 Overall Period. |
| Secondary | 75 % Responder Rate During the Last 4 Weeks of the Outpatient Maintenance Period | During the last 4 weeks of the Outpatient Maintenance Period | The 75 % responder rate is defined as the percentage of subjects who achieve a 75 % or greater reduction in focal seizure frequency. |
| Secondary | 75 % Responder Rate During the On-UCB0942 Overall Period | During the On-UCB0942 Overall Period (approximately 11 weeks) | The 75 % responder rate is defined as the percentage of subjects who achieve a 75 % or greater reduction in focal seizure frequency. |
| Secondary | Percentage of Seizure Free Days (All Seizures) During the 2-week Inpatient Period | During the 2-week Inpatient Period | For the active group, the 2-week Inpatient Period refers to the last 2 weeks of the Inpatient Period, while for the Placebo group, it refers to the first 2 weeks of the Inpatient Period. |
| Secondary | Percentage of Seizure-free Days (All Seizures) During the Outpatient Maintenance Period | During the Outpatient Maintenance Period (8 weeks) | |
| Secondary | Number of Patients Reporting at Least One Serious Adverse Event (SAE) During the Course of the Study | All study duration (approximately 19 to 20 weeks) | Number of subjects experiencing at least one serious adverse event (reported by the subject and/or caregiver or observed by the Investigator or inpatient staff). |
| Secondary | Number of Subject Withdrawals Due to Adverse Events (AEs) During the Course of the Study | All study duration (approximately 19 to 20 weeks) | Number of subjects who withdrew from the study due adverse event (reported by the subject and/or caregiver or observed by the Investigator or inpatient staff). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02495844/registered